Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Influencing Factors and Predictors for Bleeding Outcomes in Severe-Type People with Hemophilia a (PwHA) on Extended Half-Life rFVIII-Fc Prophylaxis

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Chao-Neng CHENG, Yen-Lin Liu, Chen-Hua Tsai, Jia-Ruey Tsai, Wan-Ling Ho, Shu-Hsia Hu, Yeu-Chin Chen

Blood (2024) 144 (Supplement 1): 5491.

https://doi.org/10.1182/blood-2024-209472

Published: 2024

Journal Articles

Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Yen-Lin Liu, Jia-Ruey Tsai, Chen-Hua Tsai, Wan-Ling Ho, Chao-Neng CHENG, Shu-Hsia Hu, Yeu-Chin Chen

Blood (2024) 144 (Supplement 1): 3966.

https://doi.org/10.1182/blood-2024-200872

Published: 2024

Journal Articles

The Correlation of Muscle Mass and Walking Distance with Joint Health and Functional Status in Hemophilic Arthropathy Among People with Hemophilia a (PwHA)

Chia-Yau Chang, Jia-Pei Hong, Chian-Her Lee, Shu-Huey Chen, Yen-Lin Liu, Yeu-Chin Chen, Jia-Ruey Tsai, Chen-Hua Tsai, Wan-Ling Ho, Chih-Hong Lee, Jiunn-Horng Kang

Blood (2023) 142 (Supplement 1): 3987.

https://doi.org/10.1182/blood-2023-173113

Published: 2023

Journal Articles

The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease

Yeu-Chin Chen, Chia-Yau Chang, Shin-Nan Cheng, Shiue-Wei Lai, Shu-Hsia Hu

Blood (2023) 142 (Supplement 1): 286.

https://doi.org/10.1182/blood-2023-180681

Published: 2023

Journal Articles

A Prospective, Observational, Multi-Center Study of Rurioctocog Alfa Pegol Pharmacokinetic-Guided Prophylaxis Using Mypkfit in Severe Hemophilia a Patients in Taiwan (ATTRACT-HA Study): An Interim Analysis

Jen-Yin Hou, Pei-Ying Hsieh, Ruby Lei, Chieh-Min Chen, Melody Cheng, Yeu-Chin Chen

Blood (2023) 142 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2023-177860

Published: 2023

Journal Articles

Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Ming-Chung Kuo, Chien-Chin Lin, Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Sr., Cih-En Huang, I-Ju Chiang, Chu-Han Chung, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang

Blood (2022) 140 (Supplement 1): 9709–9710.

https://doi.org/10.1182/blood-2022-156146

Published: 2022

Journal Articles

Baseline VWF:Ag Level and Body Mass Index Are Inverse Influencing Factors of Annualized Total Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Severe-Type Adult Patients with Hemophilia a (PwHA) with Episodic Treatment with rFVIII

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Jia-Ruey Tsai, Chen-Hua Tsai, Pei-Yi Lai, Yen-Lin Liu, Chao-Neng Cheng, Yeu-Chin Chen

Blood (2021) 138 (Supplement 1): 3199.

https://doi.org/10.1182/blood-2021-150822

Published: 2021

Journal Articles

Real-World Bleeding Outcomes, Weekly Factor Consumption Doses, Annualized Factor Costs in Severe-Type Patients with Hemophilia a (PwHA) before and after Switching to Extended Half-Life rFVIII-Fc Prophylaxis

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Pei-Yi Lai, Jung-Tzu Ku, Shu-Hsia Hu, Chen-Hua Tsai, Chao-Neng Cheng, Yen-Lin Liu, Jia-Ruey Tsai, Yeu-Chin Chen

Blood (2021) 138 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2021-152066

Published: 2021

Journal Articles

Clinical Predictors and Prediction Models for Frequency of Total and Joint Hemorrhage in Severe-Type Patients with Hemophilia a (PwHA) with/without Intermediate-Dose Prophylaxis Therapy with rFVIII

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Chen-Hua Tsai, Pei-Yi Lai, Yen-Lin Liu, Jia-Ruey Tsai, Chao-Neng Cheng, Yeu-Chin Chen

Blood (2021) 138 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2021-147069

Published: 2021

Journal Articles

NOVEL-1 st : A Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Tsung-Chih Chen, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Pei-Ching Hsiao, MD, Li-Yuan Bai, PhD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Jyh-Pyng Gau, MD, Po-Nan Wang, MD, Chieh-Wen Chen, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Jih-Luh Tang, MD, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137327

Published: 2020

Journal Articles

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Chia-Yau Chang, MD, Yeu-Chin Chen, MD, Chen-Hua Tsai, MD, Jia-Ruey Tsai, MD, Yen-Lin Liu, MD, Shu-Hsia Hu

Blood (2019) 134 (Supplement_1): 2406.

https://doi.org/10.1182/blood-2019-132137

Published: 2019

Journal Articles

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Hsin-An Hou, Chien-Chin Lin, MD, Ming-Chung Kuo, MD, Shyuann-Yuh Lin, MD, Jyh-Pyng Gau, MD, Ming-Chung Wang, MD, Ming-Chih Chang, MD, Tsung-Chih Chen, MD, Su-Peng Yeh, MD, Yeu-Chin Chen, MD, Cih-En Huang, MD, Chieh-Wen Chen, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Lee-Yung Shih, MD

Blood (2019) 134 (Supplement_1): 5374.

https://doi.org/10.1182/blood-2019-129645

Published: 2019

Journal Articles

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Shao-Min Han, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Li-Yuan Bai, PhD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Po-Nan Wang, MD, Jyh-Pyng Gau, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, Jih-Luh Tang, MD

Blood (2018) 132 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2018-99-112342

Published: 2018

Journal Articles

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Su-Peng Yeh, MD, Ming Yao, MD, Jih-Luh Tang, MD,PhD, Jin-Hwang Liu, MD PhD, Tzeon-Jye Chiou, MD, Tran-Der Tan, Po-Nan Wang, MD, Yeu-Chin Chen, MD, Wen-Li Hwang, MD, Ciyuan-jheng Wang, MD, Tsai-Yun Chen, MD, TA-Chih LIU, MD PhD, Ming-Sun Yu, MD, Tso-Fu Wang

Blood (2017) 130 (Supplement 1): 3229.

https://doi.org/10.1182/blood.V130.Suppl_1.3229.3229

Published: 2017

Journal Articles

Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Ching-Yuan Kuo, MD, Po-Nan Wang, MD, Wen Li Hwang, MD, Cheng-Hwai Tzeng, MD, Li-Yuan Bai, MD, Jih-Luh Tang, MD PhD, Ming-Chih Chang, MD, Sheng-Fung Lin, MD, Tsai-Yun Chen, MD, Yeu-Chin Chen, MD, Tran-Der Tan, MD, Chih-Yi Hseih, MD, Chinjune Lin, MD, Miljkovic Darko, MD, Chang Cheng-Shyong, MD

Blood (2015) 126 (23): 1593.

https://doi.org/10.1182/blood.V126.23.1593.1593

Published: 2015

Journal Articles

Different Adverse Event Profiles and Significant Hematological Improvement Are Noted When Deferasirox Was Used in Adult Patients with Chronic Transfusion-Related Iron Overload in Taiwan: Results from a Prospective Observational Clinical Trial

Bor-Sheng Ko, Ming-Chih Chang, MD, Tzeon-Jye Chiou, MD, Te-Kau Chang, MD, Yeu-Chin Chen, MD, Sheng-Fung Lin, MD, Cheng-Shyong Chang, MD, Yin-Che Lu, MD, Su-Peng Yeh, MD, Tsai-Yun Chen, MD, Wei-Yu Chen, MD

Blood (2015) 126 (23): 4554.

https://doi.org/10.1182/blood.V126.23.4554.4554

Published: 2015

Journal Articles

Von Willebrand Disease in Taiwan: A Clinical and Laboratory Studies of 52 Patients.

Yeu-Chin Chen, MD, Tsu-Yi Chao, MD,DMS, Shin-Nan Cheng, MD,DMS

Blood (2007) 110 (11): 3974.

https://doi.org/10.1182/blood.V110.11.3974.3974

Published: 2007

NARROW

Influencing Factors and Predictors for Bleeding Outcomes in Severe-Type People with Hemophilia a (PwHA) on Extended Half-Life rFVIII-Fc Prophylaxis

Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

The Correlation of Muscle Mass and Walking Distance with Joint Health and Functional Status in Hemophilic Arthropathy Among People with Hemophilia a (PwHA)

The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease

A Prospective, Observational, Multi-Center Study of Rurioctocog Alfa Pegol Pharmacokinetic-Guided Prophylaxis Using Mypkfit in Severe Hemophilia a Patients in Taiwan (ATTRACT-HA Study): An Interim Analysis

Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Baseline VWF:Ag Level and Body Mass Index Are Inverse Influencing Factors of Annualized Total Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Severe-Type Adult Patients with Hemophilia a (PwHA) with Episodic Treatment with rFVIII

Real-World Bleeding Outcomes, Weekly Factor Consumption Doses, Annualized Factor Costs in Severe-Type Patients with Hemophilia a (PwHA) before and after Switching to Extended Half-Life rFVIII-Fc Prophylaxis

Clinical Predictors and Prediction Models for Frequency of Total and Joint Hemorrhage in Severe-Type Patients with Hemophilia a (PwHA) with/without Intermediate-Dose Prophylaxis Therapy with rFVIII

NOVEL-1 st : A Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Different Adverse Event Profiles and Significant Hematological Improvement Are Noted When Deferasirox Was Used in Adult Patients with Chronic Transfusion-Related Iron Overload in Taiwan: Results from a Prospective Observational Clinical Trial

Von Willebrand Disease in Taiwan: A Clinical and Laboratory Studies of 52 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only